Osaic Holdings’s Sonnet BioTherapeutics SONN Stock Holding History

Osaic Holdings’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-175	Closed	-$568	–	8143
2025 Q3	$568	Buy	+175	New	+$776	﹤0.01%	7515
2024 Q1	–	Sell	-6	Closed	-$78	–	7387
2023 Q4	$78	Hold	6	–	–	﹤0.01%	7134
2023 Q3	$129	Hold	6	–	–	﹤0.01%	7201
2023 Q2	$490	Buy	+6	New	+$423	﹤0.01%	7057

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Osaic Holdings's SONN Position: Q4 2025 in Review

Osaic Holdings sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 175 shares — an estimated $568 sold.

Osaic Holdings first reported a position in SONN in Q2 2023 and held it in 4 quarters. The position peaked at $568 in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Osaic Holdings reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Osaic Holdings sold 175 Sonnet BioTherapeutics shares in Q4 2025, an estimated $568.
Osaic Holdings first reported a position in Sonnet BioTherapeutics in Q2 2023 and held it in 4 quarters.
Osaic Holdings's Sonnet BioTherapeutics position peaked at $568 in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Osaic Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.